JP Morgan Chase
CRDL

JP Morgan Chase’s Cardiol Therapeutics CRDL Stock Holding History

JP Morgan Chase’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.7K Buy
+48,077
New +$49.3K ﹤0.01% 6131
2024
Q4 		– Sell
-2,500
Closed -$4.95K – 7438
2024
Q3 		$4.95K Buy
+2,500
New +$5.19K ﹤0.01% 6487

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's CRDL Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 48,077 shares worth $58.7K. The stake represents ﹤0.01% of the portfolio and ranks #6131 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CRDL as recently as Q3 2024.

JP Morgan Chase first reported a position in CRDL in Q3 2024 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • JP Morgan Chase held 48,077 shares of Cardiol Therapeutics worth $58.7K as of Q1 2026.
  • Cardiol Therapeutics was a new JP Morgan Chase position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6131 holding.
  • JP Morgan Chase first reported a position in Cardiol Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.